A Study to Examine APL-130277 in Patients With Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02228590
• Other study ID #: CTH-105
• Status: Completed
• Phase: Phase 2
• Start date: August 31, 2014
• Est. completion date: November 24, 2014

Study information

• Verified date: July 2020
• Source: Sunovion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 24, 2014
• Est. primary completion date: November 24, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female =18 years of age.

2. Clinical diagnosis of Idiopathic PD

3. Receiving stable doses of L-dopa +/- other adjunctive PD therapy for at least 4 weeks before study participation.

4. At least one OFF episode per day and a total daily OFF time of > 2 hours duration.

5. Experience predictable OFF episodes in the morning on awakening prior to receiving morning dose of levodopa.

6. Stage I to III on the Hoehn and Yahr scale in the "ON" state.

7. If female and of childbearing potential, must agree to use one of the following methods of birth control:

8. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.

9. Able to understand the consent form, and to provide written informed consent.

Exclusion Criteria:

1. Atypical or secondary parkinsonism

2. Changes in L-dopa or other PD drug dosing regimens 4 weeks before the screening visit.

3. Past treatment with any form of apomorphine within 30 days of Dosing Day 1 (patients who stopped apomorphine for reasons other than lack of efficacy OR tolerability issues may be considered for the trial).

4. Female who is pregnant or lactating.

5. Contraindications to APOKYN or hypersensitive to apomorphine hydrochloride or any of the ingredients of APOKYN (notably sodium metabisulfite), or Tigan®.

6. Participation in any other clinical trial within 14 days of the screening visit.

7. Receipt of any investigational (i.e., unapproved) medication within 30 days of the screening visit.

8. Currently taking, or likely to need to take at any time during the course of the study

9. Currently taking dopamine antagonists or depleting drugs excluding anticholinergics and/or antihistamines with anticholinergic effects.

10. Drug or alcohol dependency in the past 6 months.

11. Clinically significant orthostatic hypotension.

12. Malignant melanoma or a history of previously treated malignant melanoma within 5 years.

13. Clinically significant medical surgical or laboratory abnormality in the judgment of the investigator.

14. Psychiatric disorder, including but not limited to dementia or any disorder that, in the opinion of the Investigator requires ongoing treatment that would make study participation unsafe or make treatment compliance difficult.

15. Dementia that precludes providing informed consent.

16. Potential for lack of compliance and follow-up in the judgment of the investigator.

17. Any other condition, current therapy, or prior therapy (within 30 days of the screening visit), which, in the opinion of the Investigator, would make the subject unsuitable for the study.

18. Previous neurosurgery for PD.

19. Donation of blood or plasma in the 30 days prior to dosing.

20. Presence of cankers or mouth sores.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• APL-130277
Apomorphine Hydrochloride, Sublingual Thin Film

Locations

Country	Name	City	State
United States	Parkinson's Disease and Movement Disorders Center of Boca Raton	Boca Raton	Florida
United States	Rocky Mountain Movement Disorders Center	Englewood	Colorado
United States	Banner Sun Health Research Institute	Sun City	Arizona
United States	University of South Florida Parkinson's Disease and Movement Disorders Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277	Clinical confirmation of an 'OFF' state was assessed prior to dosing and confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. The first full 'ON' dose was defined as the earliest dose in which a patient achieved a full 'ON' state as assessed by the Investigator. The percentage of patients who achieved their first full 'ON' is presented for each timepoint, regardless of the dose received, and for the study overall (i.e. all post-dose timepoints).	At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5.
Primary	Time to 'ON' State From Time of Dosing of APL-130277	Clinical confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. The time to the full 'ON' state from the time of dosing in minutes was calculated from timings noted by the Investigator and recorded in the electronic case report form (eCRF). The mean time taken for a patient to reach their first full 'ON' state following administration of APL-130277 is presented for patients who turned 'ON' for the study overall.	At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5.
Primary	Duration of 'ON' Response From Time of Dosing of APL-130277	Clinical confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. The duration of the 'ON' response was defined as the length of time in which a patient was confirmed 'ON' within a dose, and was calculated from the time noted by the Investigator and recorded in the eCRF. The mean duration of the first full 'ON' response following administration of APL-130277 is presented for patients who turned 'ON' for the study overall.	At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5.
Primary	Percentage of Patients Who Completed the Trial and Experienced an 'ON' Episode	Clinical confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. For the overall study, the percentage of patients who completed the trial, and who experienced an 'ON' episode is presented.	At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5.
Primary	Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax)	The mean Cmax values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.; Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay, with a lower limit of quantification of 0.020 nanograms per millilitre (ng/mL).	Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5.
Primary	PK Evaluation: Time of Maximum Observed Plasma Concentration (Tmax)	The median Tmax values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.; Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL.	Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5.
Primary	PK Evaluation: Time to Last Analytically Quantifiable Concentration (Tlast)	The mean Tlast values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.; Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL.	Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5.
Primary	PK Evaluation: Area Under the Plasma Concentration Time Curve, From Time 0 to 90 Minutes (AUC0-90)	The mean AUC0-90 values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.; Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL.	Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5.
Primary	PK Evaluation: Area Under the Plasma Concentration Time Curve, From Time 0 to the Last Measurable Non-zero Concentration (AUClast)	The mean AUClast values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.; Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL. The AUClast was calculated by a combination of linear and logarithmic trapezoidal methods (linear up/log down method).	Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5.
Secondary	Percentage Change in MDS-UPDRS Section III Score From Pre-dose Assessment	The Motor Function section (Section III) of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) included 33 scores based on 18-items, each anchored with 5 responses: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. The scale range was from 0 to 132, with a lower score indicating better motor function and a higher score indicating more severe motor symptoms. The percent change in the MDS-UPDRS Section III score from pre-dose to the first full ON dose or last dose for non-responders is presented. A negative change from baseline indicates an improvement.	At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5.